Soleno Investors Urged To Seek Lead Role in Securities Case Before May 5 Deadline

Overview

• Plaintiff firms on Tuesday issued fresh notices urging Soleno shareholders to move by May 5, 2026 to seek appointment as lead plaintiff.
• The putative class period covers purchases of Soleno stock from March 26 to November 4, 2025.
• According to the complaint, Soleno downplayed Phase 3 safety signals for its DCCR treatment, including reports of excess fluid retention.
• Shares dropped after key events tied to the allegations, including a short‑seller report on August 15, 2025, an SEC 8‑K on September 10, 2025 disclosing a patient death, and November 4, 2025 results outlining launch disruption.
• No class has been certified and the claims have not been proven in court, so investors are not represented unless they retain counsel or the court later certifies a class.